Our current CEO has a rich background in the biotech and retail sectors. They hold a significant leadership role at Arvinas, Inc. (NASDAQ: ARVN), where they have been pivotal in progressing the company’s research and development initiatives. Recently, they have...

Current Market Cap

$1.70B

Number of Employees

445

Total Compensation

2019 - 2023

Trending up by 6.13% last year
Showing total compensation for the last 2019 - 2023

Stock

Up by 0.00% last year

Salary

Up by 4.00% last year

Bonus

Up by 9.17% last year

Other

Up by 8.20% last year

Year

2023

Total Compensation

$1.14M

Salary

$657.70K

Board Justification

Our executive compensation policies and programs are designed to pay for performance, attract and retain individuals with superior ability, and align the executives’ interests with those of our stockholders through long-term incentives linked to specific performance.

Bonus

$473.60K

Board Justification

The annual cash bonuses paid to our named executive officers in early 2024 for 2023 performance were based solely on the achievement of corporate performance goals and each named executive officer’s target bonus amount, which remained unchanged year over year.

Other

$13.20K

Board Justification

Reflects matching contributions paid under the terms of our 401(k) plan.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was reported as vested in 2023 for the CEO.

Performance Metrics

The performance metrics for the CEO's compensation in 2023 were based on corporate goals related to clinical-stage development, preclinical pipeline and platform, and strategic and business development.

SEC Filing

From April 16, 2024

N/A

CEO of Arvinas

A

Education

Field of Expertise

Born

July 30, 2024 - 0 years ago

Is Founder?

No

Current Tenure

Not CEO of a public company

Previous Experience

Unknown